Effect of entecavir in the treatment of chronic hepatitis B virus infection and its influencing factors

Objective:To investigate the effects of entecavir(ETV) in the treatment of chronic hepatitis B(CHB) virus infection,and its influencing factors for providing the basis in rational selection of antiviral drugs.Methods:A total of 79 patients with CHB virus infection were treated with 0.5 mg/d ETV by oral from August 2014 to February 2015.The liver function,HBV-DNA and hepatitis B two and half test were detected every three months.Results:After 12,24 and 48 weeks of treatment,the HBV-DNA negative percentage(<500 copies/mL) in patients was 45.6%,60.8% and 81.0%,respectively,the alanine aminotransferase(ALT) normalization rate were 67.24%,86.20% and 96.55%,respectively,and the HBV-DNA negative percentage and ALT normalization rate increased with the time increasing(P<0.01).The treatment history,cirrhosis,HBeAg level and baseline level of HBV-DNA were related to the HBV-DNA negative percentage(P<0.05 to P<0.01).After 12 weeks of treatment,the HBV-DNA negative percentage at initial treatment group and treated group was 52.3% and 14.3%,respectively(P<0.05),and the differences of which in two groups at 24 weeks and 48 weeks of treatment were not statistically significant(P>0.05).At 12,24 and 48 weeks of treatment,the HBV-DNA negative percentage in noncirrhosis patients with HBV-DNA ≤ 7.00log₁₀ copies/mL were higher than that in cirrhosis patients with HBV-DNA >7.00log₁₀ copies/mL(P<0.05 to P<0.01).At 12 weeks and 24 weeks of treatment,the HBV-DNA negative percentage in patients with HBeAg(-) was higher than that in patients with HBeAg(+)(P<0.05 to P<0.01),and the difference of which in two groups at 48 weeks of treatment was not statistically significant(P>0.05).No obvious adverse reaction,viral breakthrough and rebound were found in 79 patients during the following up period.Conclusions:The effect of ETV in the treatment of CHB virus infection is significant and with rare adverse reactions.Initial treatment and HBeAg status have significant effect on the early efficacy of ETV in treating HBV infection,but which has not significant effect on the long-term outcome.Noncirrhosis and HBV-DNA ≤ 7.00log₁₀ copies/mL have some effects on long-term therapy,which can provide the evidence of predicting prognosis.